Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Yang

Surgery La Grange Highlands, IL Medical Doctor

NPI 1669420113 CMS profile 30089

5201 Willow Springs Rd, Suite 290, La Grange Highlands, IL 60525

Open in the dashboard

General payments

$31,775

165 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Yang of La Grange Highlands, IL is reported in the CMS Open Payments database as having received $31,775 across 165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,176 30
2024 General $11,434 21
2023 General $2,468 25
2022 General $1,452 24
2021 General $720 10
2020 General $579 7
2019 General $1,946 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Yang
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Eric Yang were reported at $13,176. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Eric Yang Surgery median Middle half National median
2019 $1,946 $253 $82–$1,521 $163
2020 $579 $131 $40–$706 $114
2021 $720 $168 $50–$904 $132
2022 $1,452 $224 $76–$1,218 $149
2023 $2,468 $253 $82–$1,255 $160
2024 $11,434 $279 $90–$1,381 $164
2025 $13,176 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $27,460 92 payments
  2. Organogenesis Inc. $1,280 20 payments
  3. Kerecis Limited $665 4 payments
  4. MIMEDX Group, Inc. $420 3 payments
  5. KCI USA, Inc $318 4 payments
  6. Urgo Medical North America, LLC $300 3 payments
  7. Intuitive Surgical, Inc. $292 4 payments
  8. Solventum Corporation $186 4 payments
  9. Tactile Systems Technology Inc $137 2 payments
  10. Aroa Biosurgery Incorporated $114 2 payments
  11. Other $603 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,025 4 payments
  2. Food and Beverage $9,257 146 payments
  3. Consulting Fee $6,325 3 payments
  4. Travel and Lodging $2,105 11 payments
  5. Education $62 1 payment
Products named General payments · program years 2019–2025
  1. OASIS $15,955 30 payments
  2. NA Sports Med Knee $12,010 3 payments
  3. GRAFIX Other Advanced Wound Management $11,551 14 payments
  4. GRAFIX Other Advanced Wound Management $8,968 16 payments
  5. GRAFIX PL Other Advanced Wound Management $8,882 21 payments
  6. GRAFIX XC Other Advanced Wound Management $7,552 2 payments
  7. GRAFIX PL Other Advanced Wound Management $5,962 8 payments
  8. GRAFIX XC Other Advanced Wound Management $5,547 3 payments
  9. STRAVIX $4,924 10 payments
  10. NA Sports Med Resection $4,585 2 payments
  11. Other $18,625 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

99

Median for General Surgery: 59

Drug cost

$2,149

Median for General Surgery: $393

Branded share of claims

0%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pentoxifylline Generic 99 $2,149

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$85,287

Medicare's payments for the services billed

Medicare patients

136

Average age 77

Services billed

1,298

66 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Diabetes 54%
Ischemic heart disease 54%
Chronic kidney disease 54%
Heart failure 53%
Atrial fibrillation 46%
COPD 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record